AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 2.68 USD Market Closed
Market Cap: 265.2m USD
Have any thoughts about
AC Immune SA?
Write Note

AC Immune SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AC Immune SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
AC Immune SA
NASDAQ:ACIU
Cash from Financing Activities
CHf40.1m
CAGR 3-Years
51%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Cash from Financing Activities
$73.9m
CAGR 3-Years
-47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Financing Activities
$354.1m
CAGR 3-Years
-19%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash from Financing Activities
-CHf1.2m
CAGR 3-Years
N/A
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash from Financing Activities
-CHf53.4m
CAGR 3-Years
N/A
CAGR 5-Years
-67%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cash from Financing Activities
CHf666k
CAGR 3-Years
-66%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
No Stocks Found

AC Immune SA
Glance View

Market Cap
265.9m USD
Industry
Biotechnology

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

ACIU Intrinsic Value
12.88 USD
Undervaluation 79%
Intrinsic Value
Price

See Also

What is AC Immune SA's Cash from Financing Activities?
Cash from Financing Activities
40.1m CHF

Based on the financial report for Sep 30, 2024, AC Immune SA's Cash from Financing Activities amounts to 40.1m CHF.

What is AC Immune SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-4%

Over the last year, the Cash from Financing Activities growth was 1 836%. The average annual Cash from Financing Activities growth rates for AC Immune SA have been 51% over the past three years , -4% over the past five years .

Back to Top